Big Flats, NY, September 26, 2014 – X-GEN Pharmaceuticals, Inc. announced today that it is re-launching Nystatin Topical Powder USP, a generic product AT rated to Mycostatin®. Nystatin Topical Powder is an antibiotic used to treat skin infections caused by a wide variety of yeasts.
X-GEN received FDA approval for Nystatin Topical in December of 2004 and is moving forward with a commercial launch due to the increase of market demand in recent years. When discussing the launch, Corporate Vice-President Rob Liles stated that, “As a small company X-GEN is able to remain flexible and we always look for ways to make the best use of our product pipeline. Sometimes it is about finding the right time to release a product into the market.” This addition of our product to the X-GEN portfolio continues to demonstrate our commitment to the healthcare industry and improving lives through the continued availability of low-cost, generic alternative medicines.
X-GEN Pharmaceuticals, Inc. is focused on the development, manufacture and delivery of specialty pharmaceutical products which serve the healthcare community as effective, generic treatment choices. X-GEN’s expanding product line offers a broad range of dosage forms including injectables, anti-infective solutions, oral solids, powders for prescription compounding and inhalants. For further information about X-GEN Pharmaceuticals call (866) 390-4411, or visit the web-site at www.x-gen.us.